Results 271 to 280 of about 10,318 (317)

Adverse Liver and Renal Outcomes After Initiating SGLT-2i and GLP-1RA Therapy Among Patients With Diabetes and MASLD. [PDF]

J Diabetes
Krishnan A, Schneider CV, Mukherjee D, Woreta TA, Alqahtani SA.   +4 more
europepmc   +1 more source

GLP-1RA and SGLT2i Medications for Type 2 Diabetes and Alzheimer Disease and Related Dementias.

JAMA Neurol
Tang H, Donahoo WT, DeKosky ST, Lee YA, Kotecha P, Svensson M, Bian J, Guo J.   +7 more
europepmc   +1 more source

GLP-1RA Promotes Beige Differentiation in Adipose Tissue

Advances in Clinical Medicine
openaire   +1 more source

Letter: Methodological Concerns Regarding GLP-1RA Effects on MASLD Outcomes

Clinical and Molecular Hepatology
openaire   +2 more sources

Comment on: GLP-1RA and SGLT2i utilization in people with type 2 diabetes with atherosclerotic cardiovascular disease (ASCVD) or at high risk of ASCVD in the Gulf Region. [PDF]

Saudi Med J
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Molecular Mechanisms Underlying the Cardiovascular Benefits of SGLT2i and GLP-1RA

Current Diabetes Reports, 2018
In addition to their effects on glycemic control, two specific classes of relatively new anti-diabetic drugs, namely the sodium glucose co-transporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) have demonstrated reduced rates of major adverse cardiovascular events (MACE) in subjects with type 2 diabetes (T2D) at high ...
Mansoor Husain
exaly   +3 more sources

GLP-1RA and SGLT2i: Cardiovascular Impact on Diabetic Patients

Current Hypertension Reviews, 2021
Background:Diabetes is a chronic disease with high complexity that demands strategic medical care with a multifactorial risk-reduction approach. Over the past decade, the treatment of type 2 diabetes mellitus (T2DM) has entirely changed. One of the paradigm changes has been the arrival of new drugs that reduce cardiovascular risk beyond the reduction ...
Aschner Pablo, Blanc Evelyn, Folino Claudia, Morosán A. Yanina   +3 more
openaire   +2 more sources

The GLP-1RAs: From Evolution to Revolution

The Singapore Family Physician, 2022
Research on incretin hormones has advanced considerably over the past few decades. Although the initial molecule – glucose-dependent insulinotropic polypeptide – failed to stimulate insulin secretion in patients with type 2 diabetes, it led to the discovery of glucagon-like peptide 1 (GLP-1). As GLP-1 impacts on various tissues and cells throughout the
openaire   +1 more source

GLP-1RA based therapies in the young and old

Current Opinion in Endocrinology, Diabetes & Obesity
Purpose of review Obesity is recognized as a “gateway” chronic, progressive disease of dysfunctional adipocytes. Glucagon-like peptide-1 receptor agonist-based therapies (GLP1BTs), including glucagon-like peptide-1 receptor agonists (GLP-1 RAs) with/without glucose-dependent insulinotropic polypeptide (GIP), have demonstrated ...
Georgia, Rigas, Shirley, Alexander, Cilla J, Haywood   +2 more
openaire   +2 more sources

Semaglutide 2.4 Mg: The Latest GLP-1RA Approved for Obesity

Journal of Investigative Medicine, 2022
Ricardo Villela, Ricardo Correa
openaire   +2 more sources